Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Biogen | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Biogen

SPINRAZA drives growth in the quarter with sales up 73%

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biogen
3Q Revenues: $3.4 billion (+12%)
3Q Earnings: $1.4 billion (+18%)
YTD Revenues: $9.9 billion (+11%)
YTD Earnings: $3.5 billion (+24%)
Comments: Multiple sclerosis (MS) revenues were relatively flat at $2.3 billion in the quarter, including approximately $137 million in royalties on the sales of OCREVUS (+112%). TECFIDERA sales were $1.1 billion, up 2% in the quarter. Avonex sales were down 10% to $482 million. TYSABRI sales were flat at $470 million. Revenue growth was driven in part by SPINRAZA, which contributed $468 million in global revenues, up 73%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters